Researchers have reported encouraging results from a small study examining intravesical instillation of a botulinum toxin/dimethyl sulfoxide (DMSO) solution as a treatment for refractory idiopathic overactive bladder (OAB).
Watson Pharmaceuticals, Corona, Calif., has received approval for Gelnique (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB).
The procedure is ideal in this population because it is minimally invasive and highly efficacious
Idiopathic overactive bladder (OAB) is a common condition in the United States, with a prevalence of 16% for men and 16.9% for women (World J Urol. 2003;20:327-336). OAB is costly, with related expenditures for 2000 estimated
Increased bladder sensation and detrusor overactivity are the most frequent urodynamic findings of overactive bladder (OAB) in women with diabetes, researchers in Taiwan reported in Neurourology and Urodynamics (2009; published online ahead of print).
Gelnique (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, has received FDA approval.
Toviaz (fesoterodine fumarate), manufactured by Schwarz Pharma of Zwickau, Germany, and distributed by Pfizer, has been approved to help patients suffering from overactive bladder (OAB).
PARIS—Investigators are predicting a significant increase in the number of individuals with lower urinary tract symptoms (LUTS) over the coming decade.
PARIS—The severity of a patient’s overactive bladder (OAB) symptoms prior to treatment with fixed-dose darifenacin (Enablex) has no effect on treatment response, researchers announced here at the Fourth International Consultation on Incontinence.
MILAN—New data demonstrate that the investigational agent fesoterodine, at both the 4 or 8 mg per day dose, is associated with significant improvements in overactive bladder (OAB) symptoms.
